ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with Issuance of 27th U.S. Patent

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of U.S. Patent No. 11337676, protecting its method for optimizing radiofrequency energy delivery using Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent marks the 27th issued in the U.S. and contributes to ENDRA's strategy of advancing hybrid ultrasound imaging systems. Currently, ENDRA holds 90 IP assets globally and aims to address unmet clinical needs, primarily targeting Non-Alcoholic Fatty Liver Disease (NAFLD) and other applications.

Positive

• Issuance of U.S. Patent No. 11337676 enhances protection for TAEUS technology.
• Total of 90 IP assets globally, including 47 patents issued.
• Focus on addressing unmet clinical needs with potential high market demand.

Negative

• None.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that the United States Patent & Trademark Office has issued a new patent to ENDRA, U.S. Patent No. 11337676 (the ‘676 patent) titled “Acoustically Compatible Radio-frequency Applicator Method and System.” The ‘676 patent protects ENDRA's method and system for optimizing the delivery of radiofrequency (RF) energy to tissue using TAEUS, and serves as the parent patent for applications being prosecuted in China and in Europe.

“This issued patent is our 27^th in the United States and supports our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our IP portfolio currently stands at 90 assets, including 47 patents issued globally.”

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005359/en/

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com

Investor Relations:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

YBriggs@lhai.com

Source: ENDRA Life Sciences Inc.

FAQ

What is the significance of ENDRA's new patent issued on U.S. Patent No. 11337676?

The patent protects ENDRA's method for optimizing radiofrequency energy delivery using TAEUS technology, enhancing its competitive edge in ultrasound diagnostics.

How many patents does ENDRA Life Sciences currently hold?

ENDRA Life Sciences holds a total of 90 IP assets globally, including 47 patents issued.

What clinical applications is ENDRA targeting with its TAEUS technology?

ENDRA's TAEUS technology primarily targets Non-Alcoholic Fatty Liver Disease (NAFLD) and additional clinical applications such as visualization of tissue temperature during surgical procedures.

When was the patent for ENDRA's TAEUS technology issued?

The U.S. Patent No. 11337676 was issued recently but the exact date was not specified in the press release.